enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Switching Antidepressants: Safety, Side Effects & Other ... - AOL

   www.aol.com/lifestyle/switching-antidepressants...

   Taper and conservative switch with a medication-free washout period. Since some tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) can cause harmful interactions if used ...

3. Is It Time to Switch from Zoloft to Prozac? How to Tell

   www.aol.com/switching-zoloft-prozac-heres-expect...

   Switching From Zoloft to Prozac: Final Thoughts. Thinking about swapping out your current medication for a new antidepressant is a big decision — but you don’t have to do it alone. With the ...

4. Equianalgesic - Wikipedia

   en.wikipedia.org/wiki/Equianalgesic

   An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics (drugs used to relieve pain). Equianalgesic charts are used for calculation of an equivalent dose (a dose which would offer an equal amount of analgesia) between different analgesics. [1]

5. Treatment-resistant depression - Wikipedia

   en.wikipedia.org/wiki/Treatment-resistant_depression

   There is support for the effectiveness of switching people to a different SSRI; 50% of people that were non-responsive after taking one SSRI were responsive after taking a second type. Switching people with treatment-resistant depression to a different class of antidepressants may also be effective.

6. List of psychiatric medications by condition treated - Wikipedia

   en.wikipedia.org/wiki/List_of_psychiatric...

   This is a list of psychiatric medications used by psychiatrists and other physicians to treat mental illness or distress.. The list is ordered alphabetically according to the condition or conditions, then by the generic name of each medication.

7. Selective serotonin reuptake inhibitor - Wikipedia

   en.wikipedia.org/wiki/Selective_serotonin...

   [6] [11] The 2008 meta-analysis combined 35 clinical trials submitted to the Food and Drug Administration (FDA) before licensing of four newer antidepressants (including the SSRIs paroxetine and fluoxetine, the non-SSRI antidepressant nefazodone, and the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine).